“With the upcoming release of preliminary topline safety and efficacy results from Part 1A of the Phase 2 preeclampsia study, DiaMedica is entering what we believe will be an exciting phase in the history of our company,” said Rick Pauls, President and CEO of DiaMedica Therapeutics (DMAC). “Building on this data, we believe DM199 has an opportunity to become a treatment option for preeclampsia, which is among the most underserved conditions in medicine today with no approved therapeutics.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DMAC:
- DMAC Upcoming Earnings Report: What to Expect?
- Buy Rating for Diamedica Therapeutics Driven by Promising DM199 Developments and Upcoming Trial Results
- DiaMedica Therapeutics price target raised to $10 from $7 at H.C. Wainwright
- DiaMedica Therapeutics Reports 2024 Financial Results
- DiaMedica Therapeutics’ Optimistic Earnings Call Highlights